GABA and Schizophrenia: A Review of Basic Science and Clinical Studies

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 601-640

  Wassef, Adel ^a   Baker, Jeffrey ^b   Kochan, Lisa D ^b  

^a University of Texas Harris County Psychiatric Center   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; KETANSERIN; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; QUETIAPINE; RECEPTOR SUBUNIT; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SERTINDOLE; STEROID; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

4 AMINOBUTYRIC ACID METABOLISM; 4 AMINOBUTYRIC ACID UPTAKE; AGITATION; BIOSYNTHESIS; BRAIN CORTEX; CADAVER; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; GENETIC ASSOCIATION; HUMAN; LONG TERM CARE; MONOTHERAPY; NEUROANATOMY; NEUROPATHOLOGY; NONHUMAN; POLYPHARMACY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; WORKING MEMORY;

ANIMALS; CLINICAL TRIALS; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA-A; SCHIZOPHRENIA;

EID: 0344033607     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000095349.32154.a5     Document Type: Review

References (256)

1. Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. [Review] [49 refs]. J Clin Psychopharmacol. 1999;19:222-232.
2. Awapara J, Landua AJ, Fuerst R. Free-aminobutyric acid in brain. J Biol Chem. 1950;187:35-39.
3. Roberts E, Frankel S. Gamma-Aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem. 1950;187:55-63.
4. Udenfriend S. Identification of aminobutyric acid in brain by the isotope derivative method. J Biol Chem. 1950;187:65-69.
5. Erlander MG, Tillakaratne NJ, Feldblum S, et al. Two genes encode distinct glutamate decarboxylases. Neuron. 1991;7:91-100.
6. Erlander MG, Tobin AJ. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. [Review] [120 refs]. Neurochem Res. 1991;16:215-226.
7. Fykse EM, Fonnum F. Uptake of gamma-aminobutyric acid by a synaptic vesicle fraction isolated from rat brain. J Neurochem. 1988;50:1237-1242.
8. Kish PE, Fischer-Bovenkerk C, Ueda T. Active transport of gamma-aminobutyric acid and glycine into synaptic vesicles. Proceedings of the National Academy of Sciences of the United States of America. 1989;86: 3877-3881.
9. Radian R, Kanner BI. Stoichiometry of sodium- and chloride-coupled gamma-aminobutyric acid transport by synaptic plasma membrane vesicles isolated from rat brain. Biochemistry. 1983;22:1236-1241.
10. Keynan S, Kanner BI. Gamma-aminobutyric acid transport in reconstituted preparations from rat brain: coupled sodium and chloride fluxes. Biochemistry. 1988;27:12-17.
11. Cooper JR, Bloom FE, Roth RH. Amino Acid Transmitters. In: Biochemical Basis of Neuropharmacology. New York: Oxford Univ. Press, 1996;128-130.
12. Haefely WE, Martin JR, Richards JG, et al. The multiplicity of actions of benzodiazepine receptor ligands. [Review] [22 refs]. Can J Psychiatry Rev Can Psychiatrie. 1993;38(suppl 4):S102-S108.
13. Whiting PJ, Wafford KA, McKernan RM. Pharmacologic Subtypes of GABAA Receptors Based On Subunit Composition. In: Martin DL, Olsen RW, eds. GABA and the Nervous System: The View At Fifty Years. Pennsylvania: Lippincott, Williams & Wilkins, 2000;113-126.
14. Marksitzer R, Benke D, Fritschy JM, et al. GABAA-receptors: drug binding profile and distribution of receptors containing the alpha 2-subunit in situ. J Recept Res. 1993;13:467-477.
15. Herb A, Wisden W, Luddens H, et al. The third gamma subunit of the gamma-aminobutyric acid type A receptor family. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89:1433-1437.
16. Puia G, Vicini S, Seeburg PH, et al. Different sites of action of neurosteroids and benzodiazepines on natural and recombinant GABAA receptors. Adv Biochem Psychopharmacol. 1992;47:103-110.
17. Scott RH, Wootton JF, Dolphin AC. Modulation of Neuronal T-type calcium channel currents by photoactivation of intracellular guanosine 5′-O(3-thio) triphosphate. Neuroscience. 1990;38:285-294.
18. Hashimoto T, Kuriyama K. In vivo evidence that GABA(B) receptors are negatively coupled to adenylate cyclase in rat striatum. J Neurochem. 1997;69:365-370.
19. Cunningham MD, Enna SJ. Evidence for pharmacologically distinct GABAB receptors associated with cAMP production in rat brain. Brain Res. 1996;720:220-224.
20. Mizukami K, Sasaki M, Ishikawa M, et al. Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett. 2000;283:101-104.
21. Mizukami K, Ishikawa M, Hidaka S, et al. Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26:393-396.
22. Mondadori C, Jaekel J, Preiswerk G. CGP 36742: the first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys. Behav Neural Biol. 1993;60:62-68.
23. Brucato FH, Levin ED, Mott DD, et al. Hippocampal long-term potentiation and spatial learning in the rat: effects of GABAB receptor blockade. Neuroscience. 1996;74:331-339.
24. Nakagawa Y, Takashima T. The GABA(B) receptor antagonist CGP36742 attenuates the baclofen- and scopolamine-induced deficit in Morris water maze task in rats. Brain Res. 1997;766:101-106.
25. Yu Z, Cheng G, Hu B. Mechanism of colchicine impairment on learning and memory, and protective effect of CGP36742 in mice. Brain Res. 1997;750:53-58.
26. Getova D, Bowery NG, Spassov V. Effects of GABAB receptor antagonists on learning and memory retention in a rat model of absence epilepsy. Eur J Pharmacol. 1997;320:9-13.
27. Getova D, Bowery NG. The modulatory effects of high affinity GABA(B) receptor antagonists in an active avoidance learning paradigm in rats. Psychopharmacology. 1998;137:369-373.
28. Marescaux C, Vergnes M, Bernasconi R. GABAB receptor antagonists: potential new anti-absence drugs. J Neural Transm. 1992;(suppl. 35):179-188.
29. Vergnes M, Boehrer A, Simler S, et al. Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur J Pharmacol. 1997;332:245-255.
30. Sayin U, Rutecki PA, Mellanby J, et al. Gamma-vinyl GABA reduces paired pulse inhibition in the rat dentate gyrus in vivo and in vitro. Epilepsy Res. 2001;44:109-117.
31. Jessa M, Nazar M, Bidzinski A, et al. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur Neuropsychopharmacol. 1996;6:55-61.
32. Erhardt S, Nissbrandt H, Engberg G. Activation of nigral dopamine Neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm-General Section. 1999;106:383-394.
33. Johnston GAR. GABA chemistry: Analogs of GABA as therapeutic and investigational agents. In: Martin DL, Olsen RW, eds. GABA and the Nervous System: The View At Fifty Years. Pennsylvania: Lippincott, Williams & Wilkins, 2000;72-80.
34. Shelton RC, Weinberger DR. X-ray computerized tomography studies in schizophrenia: A review and synthesis. In: Nasrallah HA, Weinberger DR, eds. The Neurology of Schizophrenia. Amsterdam: Elsevier Science Publishers, 1989;207-250.
35. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. [Review] [163 refs]. Biol Psychiatry. 1999;45:1099-1119.
36. Barta PE, Pearlson GD, Powers RE, et al. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry. 1990;147:1457-1462.
37. Flaum M, O'Leary DS, Swayze VW, et al. Symptom dimensions and brain morphology in schizophrenia and related psychotic disorders. J Psychiatr Res. 1995;29:261-276.
38. Carlsson A. Antipsychotic drugs and catecholamine synapses. J Psychiatr Res. 1974;11:57-64.
39. Ingvar DH. Evidence of frontal/prefrontal cortical dysfunction in chronic schizophrenia: The phenomenon of "hypofrontality" reconsidered. In: Helmchen H, Henn FA, eds. Biological Perspectives of Schizophrenia. Chichester, England: Wiley, 1987;201-211.
40. Kalus P, Senitz D, Lauer M, et al. Inhibitory cartridge synapses in the anterior cingulate cortex of schizophrenics. J Neural Transm-General Section. 1999;106:763-771.
41. Melchitzky DS, Sesack SR, Lewis DA. Parvalbumin-immunoreactive axon terminals in macaque monkey and human prefrontal cortex: laminar, regional, and target specificity of type I and type II synapses. J Comp Neurol. 1999;408:11-22.
42. Jones MW, Kilpatrick IC, Phillipson OT. Dopamine function in the prefrontal cortex of the rat is sensitive to a reduction of tonic GABA-mediated inhibition in the thalamic mediodorsal nucleus. Exp Brain Res. 1988;69:623-634.
43. Cheramy A, Nieoullon A, Glowinski J. Stimulating effects of gamma-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. J Pharmacol Exp & Ther. 1977;203:283-293.
44. Toru M, Watanabe S, Shibuya H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand. 1988;78:121-137.
45. Japha K, Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psychopharmacologia. 1999;144:347-354.
46. Meltzer HY, Dai J, Ichikawa J. Valproic acid, an anticonvulsant mood stabilizer, potentiates antipsychotic-induced dopamine release in rat medial prefrontal cortex but not nucleus accumbens. Society for Neuroscience Meeting, San Diego, 2001; (Abstract).
47. Fendt M, Schwienbacher I, Koch M. Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience. 2000;98:55-60.
48. Fendt M. Enhancement of prepulse inhibition after blockade of GABA activity within the superior colliculus. Brain Res. 1999;833:81-85.
49. Bakshi VP, Geyer MA. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp & Ther. 1997;283:666-674.
50. Tomitaka S, Tomitaka M, Tolliver BK, et al. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal Neurons in rat retrosplenial cortex. Eur J Neurosci. 2000;12: 1420-1430.
51. Ito K. The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in an animal model of methamphetamine-induced psychosis. Hokkaido Igaku Zasshi-Hokkaido J Med Sci. 1999; 74:135-144.
52. Gellman RL, Aghajanian GK. Pyramidal cells in piriform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res. 1993;600:63-73.
53. Penit-Soria J, Audinat E, Crepel F. Excitation of rat prefrontal cortical neurons by dopamine: an in vitro electrophysiological study. Brain Res. 1987;425:263-274.
54. Grobin AC, Deutch AY. Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. J Pharmacol Exp & Ther. 1998;285:350-357.
55. Benes FM, Vincent SL, Molloy R. Dopamine-immunoreactive axon varicosities form nonrandom contacts with GABA-immunoreactive Neurons of rat medial prefrontal cortex. Synapse. 1993;15:285-295.
56. Simpson MD, Slater P, Deakin JF, et al. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989; 107:211-215.
57. Bennett JPJ, Enna SJ, Bylund DB, et al. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 1979;36:927-934.
58. Simpson MD, Slater P, Royston MC, et al. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res. 1992;42:273-282.
59. Woo TU, Whitehead RE, Melchitzky DS, et al. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:5341-5346.
60. Reynolds GP, Czudek C, Andrews HB. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry. 1990;27:1038-1044.
61. Benes FM, Vincent SL, Alsterberg G, et al. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci. 1992;12:924-929.
62. Benes FM, Khan Y, Vincent SL, et al. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse. 1996;22:338-349.
63. Benes FM, Vincent SL, Marie A, et al. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience. 1996;75:1021-1031.
64. Dean B, Hussain T, Hayes W, et al. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochem. 1999;72:1593-1599.
65. Pierri JN, Chaudry AS, Woo TU, et al. Alterations in chandelier Neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry. 1999;156:1709-1719.
66. Lewis DA. GABAergic local circuit Neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res-Brain Res Rev. 2000;31: 270-276.
67. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. [Review] [252 refs]. Neuropsychopharmacology. 2001;25:1-27.
68. Lewis DA, Pierri JN, Volk DW, et al. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. [Review] [114 refs]. Biol Psychiatry. 1999;46:616-626.
69. Hare TA, Wood JH, Ballenger JC, et al. Gamma-aminobuteric acid in human cerebrospinal fluid: normal values [Letter]. Lancet. 1979;8:534-535.
70. Meldrum B. Pharmacology of GABA. [Review] [187 refs]. Clin Neuropharmacol. 1982;5:293-316.
71. Cotter D, Landau S, Beasley C, et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry. 2002;51:377-386.
72. Reynolds GP, Beasley CL. GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanal. 2001;22:95-100.
73. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high Neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 1995;52: 805-818.
74. Hanada S, Mita T, Nishino N, et al. [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 1987;40: 259-266.
75. Perlstein WM, Carter CS, Noll DC, et al. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001;158:1105-1113.
76. Sundman-Eriksson I, Blennow K, Davidsson P, et al. Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. Neuropsychobiology. 2002;45:7-11.
77. Nyiri G, Freund TF, Somogyi P. Input-dependent synaptic targeting of alpha(2)-subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. Eur J Neurosci. 2001;13:428-442.
78. Busatto GF, Pilowsky LS, Costa DC, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. [see comments]. [erratum appears in Am J Psychiatry 1997 May;154(5):722]. Am J Psychiatry. 1997;154:56-63.
79. Busatto GF, Pilowsky LS, Costa DC, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. [see comments]. [erratum appears in Am J Psychiatry 1997 May;154(5):722]. Am J Psychiatry. 1997;154:56-63.
80. Akbarian S, Huntsman MM, Kim JJ, et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cerebral Cortex. 1995;5:550-560.
81. Goldin LR, Gershon ES. Association and linkage studies of genetic marker loci in major psychiatric disorders. Psychiatr Dev. 1983; 1:387-418.
82. Jiang S, Yu J, Wang J, et al. Complete genomic sequence of 195 Kb of human DNA containing the gene GABRG2. DNA Seq. 2000;11:373-382.
83. Fritschy JM, Benke D, Johnson DK, et al. GABAA-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo. Neuroscience. 1997;81:1043-1053.
84. Papadimitriou G, Dikeos D, Daskalopoulou E, et al. Association between GABA-A receptor alpha 5 subunit gene locus and schizophrenia of a later age of onset. Neuropsychobiology. 2001;43:141-144.
85. Kurumaji A, Nomoto H, Yoshikawa T, et al. An association study between two missense variations of the benzodiazepine receptor (peripheral) gene and schizophrenia in a Japanese sample. J Neural Transm (Budapest). 2000;107:491-500.
86. Imai K, Harada S, Kawanishi Y, et al. Association analysis of an (AC)n repeat polymorphism in the GABA(B) receptor gene and schizophrenia. Am J Med Genet. 2002;114:605-608.
87. Byerley W, Bailey ME, Hicks AA, et al. Schizophrenia and GABAA receptor subunit genes. Psychiatr Genet. 1995;5:23-29.
88. Ravindranathan A, Coon H, DeLisi L, et al. Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatr Genet. 1994;4:77-80.
89. Byerley W, Coon H, Hoff M, et al. Human dopamine transporter gene not linked to schizophrenia in multigenerational pedigrees. Hum Hered. 1993;43:319-322.
90. Coon H, Byerley W, Holik J, et al. Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am J Hum Genet. 1993;52:327-334.
91. Byerley W, Plaetke R, Hoff M, et al. Tyrosine hydroxylase gene not linked to manic-depression in seven of eight pedigrees. Hum Hered. 1992;42:259-263.
92. Moises HW, Gelernter J, Giuffra LA, et al. No linkage between D2 dopamine receptor gene region and schizophrenia. [erratum appears in Arch Gen Psychiatry 1992 May;49(5):383.]. Arch Gen Psychiatry. 1991; 48:643-647.
93. Moises HW, Gelernter J, Giuffra LA, et al. No linkage between D2 dopamine receptor gene region and schizophrenia. [erratum appears in Arch Gen Psychiatry 1992 May;49(5):383.]. Arch Gen Psychiatry. 1991; 48:643-647.
94. Kunugi H, Curtis D, Vallada HP, et al. A linkage study of schizophrenia with DNA markers from chromosome 8p21-p22 in 25 multiplex families. Schizophr Res. 1996;22:61-68.
95. Gill M, McGuffin P, Parfitt E, et al. A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11. [Review] [57 refs]. Psychol Med. 1993;23:27-44.
96. Wang ZW, Black D, Andreasen NC, et al. A linkage study of chromosome 11q in schizophrenia. Arch Gen Psychiatry. 1993;50:212-216.
97. Su Y, Burke J, O'Neill FA, et al. Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome 11q in 112 Irish multiplex families. Arch Gen Psychiatry. 1993;50:205-211.
98. DeLisi LE, Shaw SH, Crow TJ, et al. A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:803-812.
99. Dann J, DeLisi LE, Devoto M, et al. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. Psychiatry Res. 1997;70: 131-143.
100. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. [Review] [183 refs]. Brain Res-Brain Res Rev. 2000;31:251-269.
101. Benes FM. The role of stress and dopamine-GABA interactions in the vulnerability for schizophrenia. [Review] [105 refs]. J Psychiatr Res. 1997;31:257-275.
102. Benes FM, Kwok EW, Vincent SL, et al. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. [see comments.]. Biol Psychiatry. 1998;44:88-97.
103. Benes FM, McSparren J, Bird ED, et al. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry. 1991;48:996-1001.
104. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol. 1998;392:402-412.
105. Payne RW, Friedlander D. Short battery of simple tests for measuring over-inclusive thinking. J Ment Sci. 1962;108:362-367.
106. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. [see comments.]. Nat Neurosci. 1998;1:318-323.
107. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. [see comments.]. Arch Gen Psychiatry. 1988;45:609-615.
108. Adler LE, Pachtman E, Franks RD, et al. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982;17:639-654.
109. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. [see comments.]. Arch Gen Psychiatry. 1986;43:114-124.
110. Rubin P, Holm S, Friberg L, et al. Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder. A regional cerebral blood flow study. Arch Gen Psychiatry. 1991;48:987-995.
111. Andreasen NC, Rezai K, Alliger R, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry. 1992; 49:943-958.
112. Catafau AM, Parellada E, Lomena FJ, et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med. 1994;35:935-941.
113. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry. 1992;49:975-982.
114. Carter C, Robertson L, Nordahl T, et al. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry. 1996;40:930-932.
115. Servan-Schreiber D, Cohen JD, Steingard S. Schizophrenic deficits in the processing of context. A test of a theoretical model. [see comments.]. Arch Gen Psychiatry. 1996;53:1105-1112.
116. Callicott JH, Ramsey NF, Tallent K, et al. Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology. 1998;18:186-196.
117. Carter CS, Perlstein W, Ganguli R, et al. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry. 1998; 155:1285-1287.
118. Meyer-Lindenberg A, Poline JB, Kohn PD, et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry. 2001;158:1809-1817.
119. McElree B. Working memory and focal attention. J Exp Psychol: Learn Mem Cogn. 2001;27:817-835.
120. Baddeley AD, Hitch G. Working Memory. In: Bower GH, ed. The psychology of Learning and motivation: Advances in research and theory. Englewood Cliffs, NJ: Prentice-Hall, 1974;47-89.
121. Braver TS, Cohen JD, Nystrom LE, et al. A parametric study of prefrontal cortex involvement in human working memory. Neuroimage. 1997;5:49-62.
122. Courtney SM, Ungerleider LG, Keil K, et al. Transient and sustained activity in a distributed neural system for human working memory. [see comments.]. Nature. 1997;386:608-611.
123. Cohen JD, Perlstein WM, Braver TS, et al. Temporal dynamics of brain activation during a working memory task. [see comments.]. Nature. 1997;386:604-608.
124. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 1974;50: 425-462.
125. Sawaguchi T, Matsumura M, Kubota K. Delayed response deficit in monkeys by locally disturbed prefrontal neuronal activity by bicuculline. Behav Brain Res. 1988;31:193-198.
126. Sawaguchi T, Matsumura M, Kubota K. Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys. Exp Brain Res. 1989;75:457-469.
127. Rao SG, Williams GV, Goldman-Rakic PS. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical Neurons engaged by working memory. J Neurosci. 2000;20:485-494.
128. Sawaguchi T, Iba M. Prefrontal cortical representation of visuospatial working memory in monkeys examined by local inactivation with muscimol. J Neurophysiol. 2001;86:2041-2053.
129. Ellis KA, Nathan PJ. The pharmacology of human working memory. [Review] [110 refs]. Int J NeuroPsychopharmacol. 2001;4:299-313.
130. Givens BS, Olton DS. Cholinergic and GABAergic modulation of medial septal area: effect on working memory. Behav Neurosci. 1990; 104:849-855.
131. Chrobak JJ, Napier TC. Intraseptal administration of bicuculline produces working memory impairments in the rat. Behav Neural Biol. 1991; 55:247-254.
132. Beninger RJ, Ingles JL, Mackenzie PJ, et al. Muscimol injections into the nucleus basalis magnocellularis of rats: selective impairment of working memory in the double Y-maze. Brain Res. 1992;597:66-73.
133. Stackman RW, Walsh TJ. Baclofen produces dose-related working memory impairments after intraseptal injection. Behav Neural Biol. 1994;61:181-185.
134. DeSousa NJ, Beninger RJ, Jhamandas K, et al. Stimulation of GABAB receptors in the basal forebrain selectively impairs working memory of rats in the double Y-maze. Brain Res. 1994;641:29-38.
135. Herzog CD, Gandhi C, Bhattacharya P, et al. Effects of intraseptal zolpidem and chlordiazepoxide on spatial working memory and high-affinity choline uptake in the hippocampus. Neurobiol Learn Mem. 2000;73:168-179.
136. Pang KC, Nocera R. Interactions between 192-IgG saporin and intraseptal cholinergic and GABAergic drugs: role of cholinergic medial septal Neurons in spatial working memory. Behav Neurosci. 1999; 113: 265-275.
137. Romanides AJ, Duffy P, Kalivas PW. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience. 1999;92:97-106.
138. Brunel N, Wang XJ. Effects of neuromodulation in a cortical network model of object working memory dominated by recurrent inhibition. J Comput Neurosci. 2001;11:63-85.
139. Kalivas PW, Jackson D, Romanidies A, et al. Involvement of pallidothalamic circuitry in working memory. Neuroscience. 2001;104:129-136.
140. Farnbach-Pralong D, Bradbury R, Copolov D, et al. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur J Pharmacol. 1998;349:R7-R8.
141. Marx CE, VanDoren MJ, Duncan GE, et al. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology. 2003;28:1-13.
142. Feng J, Cai X, Zhao J, et al. Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci. 2001;21:6502-6511.
143. Yamamoto BK, Pehek EA, Meltzer HY. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry. 1994; 55(suppl B):8-14.
144. Sakai K, Gao XM, Hashimoto T, et al. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse. 2001;39:152-160.
145. Marco E, Mao CC, Revuelta A, et al. Turnover rates of gamma-aminobutyric acid in substantia nigra, N. caudatus, globus pallidus and N. accumbens of rats injected with cataleptogenic and non-cataleptogenic antipsychotics. Neuropharmacology. 1978;17:589-596.
146. Verghese C, DeLeon J, Nair C, et al. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry. 1996;39:135-138.
147. Shirakawa O, Tamminga CA. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol. 1994;127:62-69.
148. Holcomb HH, Cascella NG, Thaker GK, et al. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry. 1996;153:41-49.
149. Korpi ER, Wong G, Luddens H. Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine. Naunyn-Schmiedebergs Arch Pharmacol. 1995;352:365-373.
150. 2-like and GABAA receptors in rat striatum. Life Sci. 2001; 69:1257-1268.
151. Bourdelais AJ, Deutch AY. The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat: an in vivo microdialysis study. Cerebral Cortex. 1994;4:69-77.
152. O'Connor WT. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J Neurosci Methods. 2001;109:31-39.
153. Grimm JW, See RE. Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience. 2000;100:507-514.
154. Osborne PG, O'Connor WT, Beck O, et al. Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res. 1994;634:20-30.
155. See RE, Chapman MA, Klitenick MA. Chronic neuroleptic administration decreases extracellular GABA in the nucleus accumbens but not in the caudate-putamen of rats. Brain Res. 1992;588:177-180.
156. O'Connor WT, Osborne PG, Ungerstedt U. Tolerance to catalepsy following chronic haloperidol is not associated with changes in GABA release in the globus pallidus. Brain Res. 1998;787:299-303.
157. Roth RH, Tam SY, Ida Y, et al. Stress and the mesocorticolimbic dopamine systems. [Review] [24 refs]. Ann NY Acad Sci. 1988;537: 138-147.
158. Freed WJ, Gillin JC, Wyatt RJ. Anomalous behavioral response to imidazoleacetic acid, a GABA agonist, in animals treated chronically with haloperidol. Biol Psychiatry. 1980;15:21-35.
159. Nair NP, Lal S, Schwartz G, et al. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Adv Biochem Psychopharmacol. 1980;24:437-441.
160. Frederiksen PK. Letter: Baclofen in the treatment of schizophrenia. Lancet. 1975;1:702.
161. Davis KL, Hollister LE, Berger PA. Letter: Baclofen in schizophrenia. Lancet. 1976;1:1245.
162. Simpson GM, Branchey MH, Shrivastava RK. Letter: Baclofen in schizophrenia. Lancet. 1976;1:966-967.
163. Simpson GM, Lee JH, Shrivastava RK, et al. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacol Bull. 1978; 14:16-18.
164. Beckmann H, Frische M, Ruther E, et al. Baclofen (para-chlorphenyl-GABA) in schizophrenia. Pharmakopsychiatr Neuro-Psychopharmakol. 1977;10:26-31.
165. Angst J, Battegay R, Bente D, et al. [On the common proceedings of a German and Swiss work group in the field of psychiatric documentation]. [German]. Schweiz Arch Neurol Neurochir Psychiatr. 1967;100: 207-211.
166. Walinder J, Wallin L, Carlsson A. Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid. N Engl J Med. 1977;296:452-453.
167. Bigelow LB, Nasrallah H, Carman J, et al. Baclofen treatment in chronic schizophrenia: a clinical trial. Am J Psychiatry. 1977;134:318-320.
168. Bigelow LB. Baclofen in chronic schizophrenia. Psychopharmacol Bull. 1977;13:4-5.
169. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35:773-782.
170. Schopf J, Hucker H. Baclofen in the treatment of schizophrenia: a pilot study. Pharmakopsychiatr Neuro-Psychopharmakol. 1977;10:89-91.
171. Potkin SG, Gillin JC, Rogol A, et al. Baclofen: lack of effect on human plasma prolactin. Commun Psychopharmacol. 1978;2:297-300.
172. Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacologia. 1978;56:145-151.
173. Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep. 1966;19:180-182.
174. Gulmann NC, Bahr B, Andersen B, et al. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand. 1976;54:287-293.
175. Kuhn R. [Neuroleptic effect of baclofen in chronic schizophrenia (author's transl)]. [German]. Arzneimittel-Forschung. 1976;26:1187.
176. Skausig OB, Korsgaard S. Hallucinations and baclofen. Lancet. 1977;1: 1258.
177. Lees AJ, Clarke CR, Harrison MJ. Hallucinations after withdrawal of baclofen. Lancet. 1977;1:858.
178. Anonymous. Hallucinations after sudden withdrawal of baclofen. Lancet. 1977;2:44-45.
179. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry. 1976;129:114-119.
180. Gündürewa V, Beckmann H, Zimmer R, et al. Effect of VPA on schizophrenic syndromes. Arzneimittelforschung/Drug Res. 1980;30:1212-1213.
181. Lautin A, Angrist B, Stanley M, et al. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry. 1980;137:240-244.
182. McElroy SL, Keck Jr PE, Pope Jr HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol. 1987;7:16-24.
183. Nagao T, Ohshimo T, Mitsunobu K, et al. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry. 1979;14:509-523.
184. Altamura AC, Basile R, Mauri M, et al. [Valpromide (Depamide) in the treatment of acute psychotic states. Open clinical study]. [French]. Acta Psychiatr Belg. 1986;86:297-304.
185. Wassef AA, Dott SG, Harris A, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol. 2000; 20:357-361.
186. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
187. Wassef AA, Hafiz NG, Hampton D, et al. Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol. 2001;21: 21-26.
188. Dose M, Hellweg R, Yassouridis A, et al. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry. 1998;31:122-125.
189. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on halopefidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999; 19: 310-315.
190. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182-192.
191. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry. 1992;49:630-636.
192. Bourguignon A, Monfort JC, de Medeiros P, et al. [Treatment of several psychotic states with the combination of valproic acid with diazepam]. [French]. Ann Med Psychol. 1984;142:1214-1218.
193. Schnetzler JP, Preaubert G, Schnetzler F. [A valproic acid-diazepam combination as an alternative to neuroleptic treatment]. [Review] [40 refs] [French]. Ann Med Psychol. 1988;146:325-339.
194. Chong SA, Tan CH, Lee EL, Liow PH. Augmentation of risperidone with valproic acid. J Clin Psychiatry. 1998;59:430.
195. Morinigo A, Martin J, Gonzalez S, et al. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside J Clin Psychiatry. 1989;11:199-207.
196. Wassef A, Watson DJ, Morrison P, et al. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol. 1989;9:45-48.
197. Ko GN, Korpi ER, Freed WJ, et al. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. Biol Psychiatry. 1985;20:209-215.
198. Chong SA, Tan CH, Lee EL, et al. Augmentation of risperidone with valproic acid. J Clin Psychiatry. 1998;59:430.
199. Shoulson I, Kartzinel R, Chase TN. Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology. 1976;26: 61-63.
200. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 2000;51:634-638.
201. Tamminga CA, Crayton JW, Chase TN. Muscimol: GABA agonist therapy in schizophrenia. Am J Psychiatry. 1978;135:746-747.
202. Tamminga CA, Neophytides A, Chase TN, et al. Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. J Clin Endocrinol Metab. 1978;47:1348-1351.
203. Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry. 1979;36:595-598.
204. Korsgaard S, Casey DE, Gerlach J, et al. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. Arch Gen Psychiatry. 1982;39:11017-1021.
205. Thaker GK, Tamminga CA, Alphs LD, et al. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry. 1987;44:522-529.
206. Casey DE, Gerlach J, Magelund G, et al. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37:1376-1379.
207. Casey DE, Gerlach J, Magelund G, et al. Gamma-Acetylenic GABA in tardive dyskinesia. Adv Biochem Psychopharmacol. 1980;24:577-580.
208. Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res. 1983;8:261-269.
209. Thaker GK, Hare TA, Tamminga CA. GABA system: clinical research and treatment of tardive dyskinesia. [Review] [61 refs]. Mod Probl Pharmacopsychiatry. 1983;21:155-167.
210. Morselli PL, Bossi L, Henry JF, et al. On the therapeutic action of SL 76 002, a new GABA-mimetic agent: preliminary observations in neuropsychiatric disorders. Brain Res Bull. 1980;5:411-414.
211. Scatton B, Zivkovic B, Dedek J, et al. gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther. 1982;220:678-688.
212. Bartholini G. GABA receptor agonists: pharmacological spectrum and therapeutic actions. [Review] [138 refs]. Med Res Rev. 1985;5:55-75.
213. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. [see comments.]. [Review] [103 refs]. Am J Psychiatry. 1991;148:714-726.
214. Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. [Review] [1407 refs]. J Clin Psychopharmacol. 1993;13:1S-169S.
215. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. [Review] [66 refs]. J Clin Psychiatry. 1990;51(Suppl):41-46.
216. Stimmel GL. Benzodiazepines in schizophrenia. [Review] [11 refs]. Pharmacotherapy. 1996;16:148S-151S.
217. Fricchione G. Catatonia: a new indication for benzodiazepines? [letter; comment]. [Review] [31 refs]. Biol Psychiatry. 1989;26:761-765.
218. Delini-Stula A, Berdah-Tordjman D. Benzodiazepines and GABA hypothesis of schizophrenia. J Psychopharmacol. 1995;9:57-63.
219. Easton MS, Janicak PG. Benzodiazepines (BZ) for the management of psychosis. [Review] [48 refs]. Psychiatr Med. 1991;9:25-36.
220. Wolkowitz OM, Turetsky N, Reus VI, et al. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. [Review] [25 refs]. Psychopharmacol Bull. 1992;28:291-295.
221. Carpenter WTJ, Buchanan RW, Kirkpatrick B, et al. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156:299-303.
222. Northoff G, Wenke J, Demisch L, et al. Catatonia: short-term response to lorazepam and dopaminergic metabolism. Psychopharmacology. 1995;122:182-186.
223. Hatta K, Takahashi T, Nakamura H, et al. The predictive value of benzodiazepine tolerance in persistently aggressive schizophrenia. Neuropsychobiology. 1999;39:196-199.
224. Kajimura N, Kato M, Okuma T, et al. Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 1994;18:477-490.
225. Johnston JD, Bristow DR. Regulation of GABA(A) receptor alpha1 protein is a sensitive indicator of benzodiazepine agonist efficacy. Eur J Pharmacol. 1998;348:321-324.
226. Follesa P, Cagetti E, Mancuso L, et al. Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res. 2001; Molecular Brain Research. 92: 138-148.
227. Follesa P, Cagetti E, Mancuso L, et al. Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res. 2001; Molecular Brain Research. 92: 138-148.
228. Longone P, Impagnatiello F, Guidotti A, et al. Reversible modification of GABAA receptor subunit mRNA expression during tolerance to diazepam-induced cognition dysfunction. Neuropharmacology. 1996;35: 1465-1473.
229. Pesold C, Caruncho HJ, Impagnatiello F, et al. Tolerance to diazepam and changes in GABA(A) receptor subunit expression in rat neocortical areas. Neuroscience. 1997;79:477-487.
230. Giusti P, Ducic I, Puia G, et al. Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther. 1993;266:1018-1028.
231. Puia G, Ducic I, Vicini S, et al. Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proceedings of the National Academy of Sciences of the United States of America 1992;89:3620-3624.
232. Haefely W, Martin JR, Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. [Review] [32 refs]. Trends Pharmacol Sci. 1990;11:452-456.
233. Facklam M, Schoch P, Bonetti EP, et al. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 1992;261: 1113-1121.
234. Delini-Stula A, Berdah-Tordjman D, Neumann N. Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings. Clin Neuropharmacol. 1992;15(suppl 1) Pt A:405A-406A.
235. Moreau JL, Jenck F, Pieri L, et al. Physical dependence induced in DBA/ 2J mice by benzodiazepine receptor full agonists, but not by the partial agonist Ro 16-6028. Eur J Pharmacol. 1990;190:269-273.
236. Schoch P, Moreau JL, Martin JR, et al. Aspects of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. [Review] [42 refs]. Biochem Soc Symp. 1993;59:121-134.
237. Thompson DM, Auta J, Guidotti A, et al. Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys. J Pharmacol Exp Ther. 1995;273:1307-1312.
238. Kleven MS, Koek W. Effects of different classes of partial benzodiazepine agonists on punished and unpunished responding in pigeons. Psychopharmacologia. 1999;144:405-410.
239. Negus SS, Mello NK, Fivel PA. Effects of GABA agonists and GABA-A receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacologia. 2000;152:398-407.
240. Giorgetti M, Javaid JI, Davis JM, et al. Imidazenil, a positive allosteric GABAA receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens shell without tolerance liability. J Pharmacol Exp Ther. 1998;287: 58-66.
241. Knoflach F, Benke D, Wang Y, et al. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Mol Pharmacol. 1996;50:1253-1261.
242. Merz WA, Alterwain P, Ballmer U, et al. Treatment of paranoid schizophrenia with the partial benzodiazepine agonists, RO 16-6028. Psychopharmacology. 1988;237:95-96.
243. Delini-Stula A, Berdah-Tordjman D. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia-a study group report. J Psychiatr Res. 1996;30:239-250.
244. Merz W. Partial benzodiazepine agonists: New concepts in the treatment of panic disorder and schizophrenia. Biol Psychiatry. 1991;29: 132S(Abstract)
245. Compagnone NA, Mellon SH. Neurosteroids: biosynthesis and function of these novel neuromodulators. [Review] [273 refs]. Front Neuroendocrinol. 2000;21:1-56.
246. Puia G, Ducic I, Vicini S, et al. Does neurosteroid modulatory efficacy depend on GABAA receptor subunit composition? Recept Channels. 1993;1:135-142.
247. Puia G, Santi MR, Vicini S, et al. Neurosteroids act on recombinant human GABAA receptors. Neuron. 1990;4:759-765.
248. Pritchett DB, Seeburg PH. gamma-Aminobutyric acid type A receptor point mutation increases the affinity of compounds for the benzodiazepine site. Proceedings of the National Academy of Sciences of the United States of America 1991;88:1421-1425.
249. Sieghart W, Karobath M. Molecular heterogeneity of benzodiazepine receptors. Nature. 1980;286:285-287.
250. Rupprecht R, di MF, Hermann B, et al. Neuroactive steroids: molecular mechanisms of action and implications for Neuropsychopharmacology. [Review] [60 refs]. Brain Res-Brain Res Rev. 2001;37:59-67.
251. Pinna G, Uzunova V, Matsumoto K, et al. Brain allopregnanolone regulates the potency of the GABA(A) receptor agonist muscimol. Neuropharmacology. 2000;39:440-448.
252. Gasior M, Carter RB, Witkin JM. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. [Review] [60 refs]. Trends Pharmacol Sci. 1999;20:107-112.
253. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. [see comments.]. [Review] [63 refs]. Trends Neurosci. 1999;22:410-416.
254. Zorumski CF, Mennerick S, Isenberg KE, et al. Potential clinical uses of neuroactive steroids. [Review] [108 refs]. Curr Opin Investig Drugs. 2000;1:360-369.
255. Barbaccia ML, Lello S, Sidiropoulou T, et al. Plasma 5alpha-androstane-3alpha, 17betadiol, an endogenous steroid that positively modulates GABA(A) receptor function, and anxiety: a study in menopausal women. Psychoneuroendocrinology. 2000;25:659-675.
256. Lloyd KG, Morselli PL, Depoortere H, et al. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav. 1983;18:957-966.